Generation bio provides update on preclinical studies for hemophilia a program

Cambridge, mass., dec. 14, 2021 (globe newswire) -- generation bio co. (nasdaq: gbio), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today provided an update on factor viii expression from a series of mouse and companion non-human primate (nhp) studies in hemophilia a, as well as an update on the development of its non-viral genetic medicine platform. generation bio's proprietary genetic medicine technology comprises a closed-ended dna (cedna) delivered via a novel, cell-targeted lipid nanoparticle (ctlnp). in july 2021 the company announced that it would incorporate its novel, proprietary rapid enzymatic synthesis (res) for cedna production into its pipeline programs. res has improved cedna purity to 99%.
GBIO Ratings Summary
GBIO Quant Ranking